New hope for kids with severe eczema: dupilumab shows promise in japanese trial
NCT ID NCT04678882
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested the drug dupilumab (given as a shot) plus steroid creams in 62 Japanese children aged 6 months to 18 years with moderate-to-severe eczema that wasn't controlled by other treatments. The goal was to see if dupilumab could improve skin symptoms and itching over 16 weeks. The trial is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (a biologic drug given as a shot under the skin)
What this could lead to
If it works, this could offer a new treatment option for Japanese children with hard-to-control eczema, reducing itch and skin inflammation.
What could go wrong
This is a completed Phase 3 trial with only 62 participants, all Japanese. Results may not apply to other groups, and dupilumab can cause side effects like injection reactions or eye problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 3920001
Hiroshima, Hiroshima, 734-8551, Japan
-
Investigational Site Number : 3920003
Sagamihara-shi, Kanagawa, 252-0392, Japan
-
Investigational Site Number : 3920006
Tsu, Mie-ken, 514-0125, Japan
-
Investigational Site Number : 3920007
Kobe, Hyōgo, 658-0082, Japan
-
Investigational Site Number : 3920008
Kobe, Hyōgo, 653-0836, Japan
-
Investigational Site Number : 3920009
Sapporo, Hokkaido, 060-0807, Japan
-
Investigational Site Number : 3920010
Yokohama, Kanagawa, 225-0015, Japan
-
Investigational Site Number : 3920011
Nagoya, Aichi-ken, 457-8510, Japan
-
Investigational Site Number : 3920012
Koto-ku, Tokyo, 136-0074, Japan
-
Investigational Site Number : 3920013
Sapporo, Hokkaido, 004-0063, Japan
-
Investigational Site Number : 3920014
Toyoake-shi, Aichi-ken, 470-1192, Japan
-
Investigational Site Number : 3920015
Fukutsu-shi, Fukuoka, 811-3217, Japan
-
Investigational Site Number : 3920016
Kumagaya-shi, Saitama, 360-0018, Japan
-
Investigational Site Number : 3920017
Yokohama, Kanagawa, 221-0825, Japan
-
Investigational Site Number : 3920019
Toyonaka-shi, Osaka, 560-0085, Japan
-
Investigational Site Number : 3920020
Sakai-shi, Osaka, 593-8324, Japan
-
Investigational Site Number : 3920021
Habikino-shi, 583-8588, Japan
-
Investigational Site Number : 3920022
Toshima-ku, Tokyo, 170-0002, Japan
-
Investigational Site Number : 3920023
Chuo-ku, Tokyo, 104-0031, Japan